FIELD: medicine.
SUBSTANCE: invention refers to medicine and pharmacy, namely to agents for inhibition of development or progression of liver cancer in hepatitis C positive patients suffering from cirrhosis, wherein the agent contains three types of amino acids, namely isoleucine, leucine and valine, wherein mass ratio of isoleucine, leucine and valine makes 1:1.5-2.5:0.8-1.7.
EFFECT: invention provides effective inhibition of development or progression of liver cancer in hepatitis C positive patients suffering from cirrhosis.
18 cl, 1 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL AGENT FOR PREVENTING AND/OR TREATING HEPATOCELLULAR CARCINOMA | 2011 |
|
RU2574009C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| PREVENTIVE OR THERAPEUTIC AGENT AGAINST VIRAL DISEASE | 2007 |
|
RU2433827C2 |
| DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
| PYRIDO [2,3-d] PYRIMIDINES, USEFUL AS HCV INHIBITORS AND SYNTHESIS METHODS THEREOF | 2006 |
|
RU2444522C2 |
| METHOD OF SCREENING HEPATIC DISORDERS, AND SYSTEM FOR IMPLEMENTING METHOD | 2013 |
|
RU2523661C1 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2762193C2 |
| COMBINED THERAPY OF PANCREATIC CANCER WITH USE OF ANTIGEN POLYPEPTIDE AND CHEMOTHERAPEUTIC AGENT | 2008 |
|
RU2472522C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING LIVER DISEASE | 2011 |
|
RU2561688C2 |
